核苷类逆转录酶抑制剂与HIV感染孕妇不良围产结局的关联:系统综述与荟萃分析
该系统综述与荟萃分析纳入22项队列研究、共124,478例HIV感染孕妇,评估不同核苷类逆转录酶抑制剂(NRTI)方案的不良围产结局风险。含富马酸替诺福韦二吡呋酯(TDF)的方案与早产、小于胎龄儿、死产和新生儿死亡风险降低相关,含齐多夫定的方案则与上述风险升高相关;阿巴卡韦未见与不良围产结局相关。作者认为研究结果支持现行WHO指南。
要点
- 与不含TDF的方案相比,含TDF方案与早产(RR 0.89)、死产(RR 0.49)和新生儿死亡(RR 0.61)风险降低相关。
- 与不含齐多夫定的方案相比,含齐多夫定方案与死产(RR 2.23)和新生儿死亡(RR 1.65)风险升高相关。
- 阿巴卡韦未观察到与不良围产结局相关;作者认为研究结果支持现行WHO指南。
核心结论
- 含富马酸替诺福韦二吡呋酯(TDF)的方案与不良围产结局风险降低相关,含齐多夫定的方案与不良围产结局风险升高相关。
- 阿巴卡韦未观察到与不良围产结局相关。
- 作者认为上述发现支持现行WHO指南。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、CINAHL、Global Health和Embase数据库。
- 纳入标准为队列研究,对象为HIV感染孕妇,干预为含不同NRTI药物的抗逆转录病毒治疗方案。
- 共纳入22项队列研究,合计124,478例HIV感染孕妇。
- 采用纽卡斯尔-渥太华量表和推荐分级的评估、制定与评价(GRADE)进行偏倚风险评估。
- 采用随机效应模型进行荟萃分析。
主要发现
- 与不含TDF的方案相比,含TDF方案与早产风险降低相关(RR 0.89,95%CI 0.81-0.97)。
- 与不含TDF的方案相比,含TDF方案与极早产(RR 0.58,95%CI 0.40-0.86)、小于胎龄儿(RR 0.76,95%CI 0.59-0.98)、重度小于胎龄儿(RR 0.60,95%CI 0.48-0.73)、死产(RR 0.49,95%CI 0.31-0.78)和新生儿死亡(RR 0.61,95%CI 0.40-0.93)风险降低相关。
- 与不含齐多夫定的方案相比,含齐多夫定方案与极早产(RR 1.59,95%CI 1.01-2.49)、小于胎龄儿(RR 1.33,95%CI 1.03-1.70)、重度小于胎龄儿(RR 1.63,95%CI 1.25-2.13)、死产(RR 2.23,95%CI 1.10-4.55)和新生儿死亡(RR 1.65,95%CI 1.08-2.52)风险升高相关。
- 在同时含拉米夫定或恩曲他滨的方案中,与含TDF方案相比,含齐多夫定方案与极早产(RR 1.62,95%CI 1.04-2.52)、小于胎龄儿(RR 1.52,95%CI 1.28-1.82)、重度小于胎龄儿(RR 1.68,95%CI 1.36-2.06)、死产(RR 2.19,95%CI 1.03-4.67)和新生儿死亡(RR 1.65,95%CI 1.08-2.52)风险升高相关。
- 阿巴卡韦未观察到与不良围产结局相关;与TDF相比,替诺福韦艾拉酚胺未观察到与低出生体重相关。
关键数值与推荐
- WHO推荐以含两种NRTI的方案作为抗逆转录病毒治疗骨干。
- WHO推荐妊娠期一线方案为富马酸替诺福韦二吡呋酯联合拉米夫定或恩曲他滨,替代方案为齐多夫定、阿巴卡韦或替诺福韦艾拉酚胺联合拉米夫定或恩曲他滨。
- 作者认为研究结果支持现行WHO指南(原文未给出具体推荐等级)。
临床怎么用
- 作者认为研究结果支持现行WHO指南,原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The WHO recommends antiretroviral therapy (ART) containing two nucleoside reverse transcriptase inhibitors (NRTIs) as backbone. WHO recommends tenofovir disoproxil fumarate combined with lamivudine or emtricitabine as first line in pregnancy, and zidovudine, abacavir or tenofovir alafenamide, combined with lamivudine or emtricitabine, as alternatives. OBJECTIVES: This study aims to evaluate the risk of adverse perinatal outcomes in pregnant women living with HIV (WLHIV) receiving different NRTIs. METHODS: Data sources included Medline, CINAHL, Global Health, and Embase. STUDY ELIGIBILITY CRITERIA: Cohort studies. PARTICIPANTS: Pregnant WLHIV. INTERVENTIONS: ART regimens containing different NRTI drugs. ASSESSMENT OF RISK OF BIAS: Newcastle-Ottawa Scale and Grading of Recommendations Assessment, Development and Evaluation. METHODS OF DATA SYNTHESIS: Random-effects meta-analysis. RESULTS: In total, 22 cohort studies including 124,478 pregnant WLHIV met the eligibility criteria. ART containing tenofovir disoproxil fumarate was associated with lower risk of preterm birth (risk ratio, 0.89; 95% CI, 0.81-0.97), very preterm birth (0.58; 0.40-0.86), small for gestational age (0.76; 0.59-0.98), very small for gestational age (0.60; 0.48-0.73), stillbirth (0.49; 0.31-0.78), and neonatal death (0.61; 0.40-0.93), compared with ART not containing tenofovir disoproxil fumarate. ART containing zidovudine was associated with an increased risk of very preterm birth (1.59; 1.01-2.49), small for gestational age (1.33; 1.03-1.70), very small for gestational age (1.63; 1.25-2.13), stillbirth (2.23; 1.10-4.55), and neonatal death (1.65; 1.08-2.52), compared with ART not containing zidovudine. For ART regimens also containing either lamivudine or emtricitabine, zidovudine was associated with an increased risk of very preterm birth (1.62; 1.04-2.52), small for gestational age (1.52; 1.28-1.82), very small for gestational age (1.68; 1.36-2.06), stillbirth (2.19; 1.03-4.67), and neonatal death (1.65; 1.08-2.52), compared with ART containing tenofovir disoproxil fumarate. Abacavir was not associated with adverse perinatal outcomes. Tenofovir alafenamide was not associated with low birthweight compared with tenofovir disoproxil fumarate. CONCLUSIONS: Tenofovir disoproxil fumarate is associated with a lower risk of adverse perinatal outcomes, whereas zidovudine is associated with an increased risk of perinatal outcomes. Abacavir is not associated with adverse perinatal outcomes. Our findings support current WHO guidelines.
引用
- Cowdell I, Beck K, Hey M, et al. Association of nucleoside reverse transcriptase inhibitors with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis. Clin Microbiol Infect. 2025. PMID: 39848582. doi:10.1016/j.cmi.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。